MacroGenics Q2 2021 Earnings Report
Key Takeaways
MacroGenics reported a net loss of $39.9 million for the quarter ended June 30, 2021, with total revenue of $30.8 million, including $3.2 million in net sales of MARGENZA. The company's cash, cash equivalents, and marketable securities were $297.3 million as of June 30, 2021.
Presented encouraging Phase 1 study data of MGC018 at ASCO.
Announced strategic collaboration with Zai Lab to develop and commercialize preclinical bispecific antibodies in oncology.
Expects to complete and share top-line results from the final analysis of OS data from the SOPHIA metastatic breast cancer Phase 3 study by the end of Q3 2021.
Plans to report interim safety and efficacy data from the MAHOGANY study at ESMO in September 2021.
MacroGenics
MacroGenics
MacroGenics Revenue by Segment
Revenue & Expenses
Visualization of income flow from segment revenue to net income